In this way, by blocking the NFκB signaling, which is an important factor for tumor progression in inflammation-related cancers, and by decreasing TNF-α and some inflammatory cytokines such as IL-6, tumor progression can be alleviated (93–95). Here, NFKB1 is linked to neoplasm.